CARY,
N.C., July 9, 2024 /PRNewswire/ -- Allucent, a
global mid-sized clinical research organization (CRO), announced
today that it has been selected by the Biomedical Advanced Research
and Development Authority (BARDA), part of the Administration for
Strategic Preparedness and Response within the U.S. Department of
Health and Human Services, for its new
Decentralized Clinical Operations for Healthcare and
Research (D-COHRe) initiative.
According to BARDA, D-COHRe will
enhance decentralized clinical study
capabilities in order to support and accelerate the
development of medical countermeasures (MCMs) and bolster the
nation's ability to prepare and respond to future public health
emergencies (PHEs).
The COVID-19 pandemic necessitated and catalyzed utilization of
decentralized healthcare, including telemedicine,
retail clinics, wellness apps, and more. At the same time, the
pandemic highlighted the need for clinical trial modernization –
specifically, the need to shift from traditional, centralized
clinical studies to more patient-centric,
decentralized clinical research that enables
participation from more locations in order to rapidly validate and
distribute broad sets of MCMs including new diagnostics, vaccines
and antivirals.
By participating in the D-COHRe program, Allucent will leverage
the shift toward decentralized healthcare and enhance
decentralized clinical study capabilities in order to
build sustainable capability and evaluate medical countermeasures
in real world environments.
"In the wake of the COVID-19 pandemic there is a pressing need
and an unprecedented opportunity to realize the potential of
decentralized clinical trials," said Mark A. Goldberg, M.D., chairman and chief
executive officer of Allucent. "Allucent is proud to partner with
BARDA on this important initiative to bolster pandemic preparedness
by enhancing decentralized clinical study
capabilities. We look forward to applying our
decentralized trial expertise to validate, pilot, and
implement new products, technologies, and approaches intended for
decentralized use, with the agility needed during a
public health emergency."
In support of the D-COHRe program, Allucent will enhance its
capabilities to deploy decentralized clinical trials,
including hybrid and fully decentralized trials using
home health, mobile health, telehealth and alternative research
sites. These diverse site models will be supported by secure data
collection technology, engagement tools for participants, and
numerous research services to facilitate the enrollment and
retention of diverse and dispersed research participants.
Over the course of the 5-year program, Allucent will focus on
enhancing innovation with decentralized care
capabilities in order to execute highly efficient and relevant
clinical research in decentralized clinical settings.
Allucent will also identify and address challenges for implementing
and conducting decentralized clinical trials and
monitor the success and sustainability of the
decentralized trial model throughout the program.
This project has been funded in whole or in part with federal
funds from the Department of Health and Human Services;
Administration for Strategic Preparedness and Response; Biomedical
Advanced Research and Development Authority; Division of Research,
Innovation and Ventures ("DRIVe"), under Agreement
number: 75A50124C00025.
About Allucent
Allucent is on a mission to help bring new therapies to
light by solving the distinct challenges of its biopharma and
government clients. Allucent is a global provider of comprehensive
drug development solutions, including consulting, clinical
operations, biometrics, and clinical pharmacology across various
therapeutic areas. With more than 30 years of experience in
over 60 countries, Allucent's individualized partnership
approach provides experience-driven insights and expertise to
assist its clients in successfully navigating the complexities of
delivering novel treatments to patients.
Visit Allucent.com for more information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/allucent-awarded-5-year-barda-agreement-aimed-at-enhancing-and-accelerating-decentralized-clinical-trials-for-medical-countermeasure-development-302191338.html
SOURCE Allucent